Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Veracyte Inc
(NQ:
VCYT
)
25.56
+2.97 (+13.15%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Veracyte Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Trading SMID Biotech Stocks In A Volatile Market
July 01, 2024
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a...
Via
Talk Markets
Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness
June 10, 2024
On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a...
Via
Benzinga
Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors
June 03, 2024
From
Veracyte, Inc.
Via
Business Wire
A Glimpse Into The Expert Outlook On Veracyte Through 4 Analysts
May 08, 2024
Via
Benzinga
Recap: Veracyte Q4 Earnings
February 22, 2024
Via
Benzinga
Earnings Outlook For Veracyte
February 21, 2024
Via
Benzinga
Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
May 22, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in Upcoming Investor Conferences
May 15, 2024
From
Veracyte, Inc.
Via
Business Wire
VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q1 2024
May 07, 2024
VCYT stock results show that Veracyte beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Veracyte Announces First Quarter 2024 Financial Results
May 07, 2024
From
Veracyte, Inc.
Via
Business Wire
14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
May 06, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
April 22, 2024
From
Veracyte, Inc.
Via
Business Wire
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
April 22, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
April 16, 2024
From
Veracyte, Inc.
Via
Business Wire
Cathie Wood's Ark Invest Dumps $17M In Coinbase Shares As The Exchange Grappled With Disruption Amid Bitcoin Rally
February 28, 2024
On Wednesday, Cathie Wood-led Ark Invest made a significant move by selling over $17 million worth of Coinbase Global Inc (NASDAQ:COIN) shares.
Via
Benzinga
Cathie Wood's Ark Invest Sheds $9.3M Worth Of Coinbase Shares Amid Bitcoin Rally — Robinhood Stock Also Sold
February 27, 2024
On Tuesday, Cathie Wood-led Ark Invest adjusted its portfolio, making significant trades.
Via
Benzinga
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
February 27, 2024
From
Veracyte, Inc.
Via
Business Wire
Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed
February 26, 2024
On Monday, Cathie Wood-led Ark Invest adjusted its portfolio, notably selling shares of cryptocurrency-related companies such as Robinhood Markets Inc (NASDAQ:HOOD) and Coinbase Global Inc (NASDAQ:
Via
Benzinga
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
February 26, 2024
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off.
Via
InvestorPlace
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
February 22, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
February 21, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
February 08, 2024
From
Veracyte, Inc.
Via
Business Wire
Earnings Scheduled For February 22, 2024
February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.
Via
Benzinga
Veracyte Completes Acquisition of C2i Genomics
February 06, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
January 08, 2024
From
Veracyte, Inc.
Via
Business Wire
Cathie Wood's Ark Invest Buys Over $92M Worth Of ProShares Bitcoin ETF, Sells Coinbase, Block And Palantir Shares
December 27, 2023
On Wednesday, Cathie Wood-led Ark Invest made a significant move in the cryptocurrency space, purchasing over $92 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO).
Via
Benzinga
Topics
ETFs
Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 12, 2023
From
Veracyte, Inc.
Via
Business Wire
Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
December 01, 2023
From
Veracyte, Inc.
Via
Business Wire
Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
November 29, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023
November 22, 2023
From
Veracyte, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.